ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Operating Expenses history
Currency unavailable · from the income statement
No Operating Expenses data reported for this period type.
Operating Expenses vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $264.22M USD | +15.6% | +14.4% | 368.0% | |
| LTM Mar 2026 | $214.24M USD | +41.4% | +20.6% | 667.8% | |
| LTM Mar 2026 | $178.28M USD | +5.9% | +11.3% | 223.5% | |
| LTM Mar 2026 | $162.94M USD | -22.5% | +20.8% | 4039.1% | |
| LTM Mar 2026 | $130.57M USD | -39.9% | -10.4% | 287.9% | |
| FY2025 | $95.43M USD | — | — | 512.6% | |
| LTM Mar 2026 | $87.2M USD | — | +16.9% | 9463.1% | |
| LTM Mar 2026 | €58.51M EUR | +12.1% | -7.3% | 435.3% | |
| LTM Mar 2026 | $53.82M USD | +43.6% | +32.6% | — | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +12.1% | +15.6% | 473.9% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.